{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:19:04Z","timestamp":1791472744632,"version":"4.3.4"},"reference-count":245,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006641","name":"UNICEF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006641","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vaccine.2025.127971","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:37:13Z","timestamp":1763602633000},"page":"127971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Value profile for Malaria vaccines and monoclonal antibodies"],"prefix":"10.1016","author":[{"given":"Ashley J.","family":"Birkett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ansah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gyapong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanelle","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Penny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Shirey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Slutsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Ethelston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Westercamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127971_bb0005","unstructured":"World Health Organization. World malaria report 2024 2024. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024 (accessed December 23, 2024)."},{"key":"10.1016\/j.vaccine.2025.127971_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature15535","article-title":"The effect of malaria control on plasmodium falciparum in Africa between 2000 and 2015","volume":"526","author":"Bhatt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127971_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033883","article-title":"Trends in malaria prevalence and health related socioeconomic inequality in rural western Kenya: results from repeated household malaria cross-sectional surveys from 2006 to 2013","volume":"9","author":"Were","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127971_bb0025","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0030","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12936-020-03460-w","article-title":"Impact of plasmodium falciparum gene deletions on malaria rapid diagnostic test performance","volume":"19","author":"Gatton","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0040","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.apar.2021.08.006","article-title":"Epidemiology of the zoonotic malaria plasmodium knowlesi in changing landscapes","volume":"113","author":"Cuenca","year":"2021","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025510","article-title":"Determinants of malaria transmission at the population level","volume":"7","author":"Bousema","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/589288","article-title":"Editorial commentary: mortality associated with severe plasmodium falciparum malaria increases with age","volume":"47","author":"Olliaro","year":"2008","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2025.127971_bb0060","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12936-020-03336-z","article-title":"Pathophysiology and neurologic sequelae of cerebral malaria","volume":"19","author":"Schiess","year":"2020","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0065","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1473-3099(07)70021-X","article-title":"Epidemiology and burden of malaria in pregnancy","volume":"7","author":"Desai","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0075","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(13)60851-X","article-title":"Socioeconomic development as an intervention against malaria: a systematic review and meta-analysis","volume":"382","author":"Tusting","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127971_bb0080","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2875-11-122","article-title":"Malaria resurgence: a systematic review and assessment of its causes","volume":"11","author":"Cohen","year":"2012","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4269\/ajtmh.2003.68.121","article-title":"Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya","volume":"68","author":"Hawley","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0100","series-title":"Pediatric mortality in Africa: Plasmodium falciparum Malaria as a cause or risk?","author":"Snow","year":"2004"},{"key":"10.1016\/j.vaccine.2025.127971_bb0105","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0110","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4269\/ajtmh.19-0386","article-title":"The economic burden of malaria: revisiting the evidence","volume":"101","author":"Sarma","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0115","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.4269\/ajtmh.2001.64.ii","article-title":"The malaria burden and Africa","volume":"64","author":"Samba","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0120","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0125","article-title":"Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria","volume":"7","author":"Cola","year":"2022","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb0130","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(09)61258-7","article-title":"Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials","volume":"374","author":"Aponte","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127971_bb0135","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0140","series-title":"Malaria vaccine introduction \u2013 technical resources","author":"Furrer","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127971_bb0145","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of Phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"RTS,S Clinical Trials Partnership","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127971_bb0155","article-title":"High-impact results from the Malaria Vaccine implementation Programme (MVIP)","author":"Bawa","year":"2023","journal-title":"Am Trop Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0160","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127971_bb0165","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0170","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0175","series-title":"WHO guidelines for malaria","first-page":"2021","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0180","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12936-022-04144-3","article-title":"Assessing the safety, impact and effectiveness of RTS,S\/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up","volume":"21","author":"Praet","year":"2022","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0190","series-title":"Full evidence report on the R21\/matrix-M malaria vaccine","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127971_bb0195","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2025.127971_bb0200","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0205","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21775-3","article-title":"Predicting the public health impact of a malaria transmission-blocking vaccine","volume":"12","author":"Challenger","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127971_bb0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","article-title":"Global epidemiology of plasmodium vivax","volume":"95","author":"Howes","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0220","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1016\/j.vaccine.2009.07.018","article-title":"Guidance on the evaluation of plasmodium vivax vaccines in populations exposed to natural infection","volume":"27","author":"Mueller","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.parepi.2020.e00145","article-title":"Future use-cases of vaccines in malaria control and elimination","volume":"10","author":"Penny","year":"2020","journal-title":"Parasite Epidemiol Control"},{"key":"10.1016\/j.vaccine.2025.127971_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003193","article-title":"What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines","volume":"3","author":"Penny","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb0235","author":"Gavi"},{"key":"10.1016\/j.vaccine.2025.127971_bb0240","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0245","series-title":"PATH \u2014 RTS,S Malaria Vaccine Implementation","author":"Good Ventures","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127971_bb0255","unstructured":"World Health Organization. Beyond the numbers: the real-world impact of the malaria vaccine in Kenya 2023. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/beyond-the-numbers--the-real-world-impact-of-the-malaria-vaccine-in-kenya (accessed April 20, 2023)."},{"key":"10.1016\/j.vaccine.2025.127971_bb0260","unstructured":"World Health Organization. SAGE\/MPAG working group on malaria vaccines n.d. https:\/\/www.who.int\/initiatives\/malaria-vaccine-implementation-programme\/sage-mpag-working-group (accessed April 21, 2023)."},{"key":"10.1016\/j.vaccine.2025.127971_bb0265","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0270","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0275","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0280","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0285","author":"Global Health Council, Washington DC"},{"key":"10.1016\/j.vaccine.2025.127971_bb0290","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0295","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0300","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0305","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0310","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0315","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0320","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0325","author":"The Global Fund"},{"key":"10.1016\/j.vaccine.2025.127971_bb0330","author":"Unitaid"},{"key":"10.1016\/j.vaccine.2025.127971_bb0335","series-title":"RTS,S\/AS01 malaria vaccine: EDCTP contributions and next steps","author":"The European & Developing Countries Clinical Trials Partnership (EDCTP)","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0340","series-title":"Public portal of EDCTP2-funded projects","author":"The European & Developing Countries Clinical Trials Partnership (EDCTP)","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127971_bb0345","series-title":"GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S\/AS01E malaria vaccine | GSK","author":"PATH","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0350","series-title":"Serum Institute of India","author":"Serum Institute of India","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127971_bb0355","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0360","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0365","series-title":"RTS,S malaria vaccine","author":"MedAccess","year":"2023"},{"key":"10.1016\/j.vaccine.2025.127971_bb0370","author":"Roll Back Malaria Partnership"},{"key":"10.1016\/j.vaccine.2025.127971_bb0375","article-title":"Communique: west African high level vaccines manufacturers meeting","author":"African Union","year":"2022","journal-title":"Afr CDC"},{"key":"10.1016\/j.vaccine.2025.127971_bb0380","author":"Union Africain"},{"key":"10.1016\/j.vaccine.2025.127971_bb0390","article-title":"Statement by USAID administrator Samantha power: celebrating a landmark moment in protecting children from Malaria","author":"Initiative","year":"2021","journal-title":"PMI"},{"key":"10.1016\/j.vaccine.2025.127971_bb0395","author":"USAID, CDC. U.S"},{"key":"10.1016\/j.vaccine.2025.127971_bb0400","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb0405","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0410","series-title":"Seasonal vaccination with the RTS,S\/AS01 malaria vaccine given with or without seasonal malaria chemoprevention: extension of a randomised, double-blind Phase 3 trial until children reach the age of five years (NCT04319380)","author":"London School of Hygiene and Tropical Medicine","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0415","series-title":"Extension to study MALARIA-055 PRI (NCT00866619) for evaluation of long-term efficacy, safety and Immunogenicity of GSK Biologicals' candidate malaria vaccine (SB257049) in infants and children in Africa","author":"GlaxoSmithKline","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0420","series-title":"R21\/matrix-M in African children against clinical malaria","author":"University of Oxford","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0425","author":"National Agency for Food and Drug Administration and Control"},{"key":"10.1016\/j.vaccine.2025.127971_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-007870","article-title":"Should India be considering deployment of the first malaria vaccine RTS,S\/AS01?","volume":"7","author":"Rahi","year":"2022","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb0435","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0440","series-title":"Technical consultation on the malaria rebound phenomenon: Report on a virtual meeting, 22\u201323 march 2022","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0445","series-title":"Assessing the programmatic suitability of vaccine candidates for WHO prequalification","author":"WHO Department of Immunization Vaccines and Biologicals (IVB)","year":"2015"},{"key":"10.1016\/j.vaccine.2025.127971_bb0450","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0455","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2014.07.030","article-title":"Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward","volume":"32","author":"Nunes","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0460","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1475-2875-13-283","article-title":"Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting","volume":"13","author":"Cheng","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0465","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s12936-019-3028-z","article-title":"A review of the WHO malaria rapid diagnostic test product testing programme (2008-2018): performance, procurement and policy","volume":"18","author":"Cunningham","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0470","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00436-022-07512-9","article-title":"Malaria diagnostic methods with the elimination goal in view","volume":"121","author":"Oyegoke","year":"2022","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2025.127971_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232874","article-title":"Point prevalence of asymptomatic plasmodium infection and the comparison of microscopy, rapid diagnostic test and nested PCR for the diagnosis of asymptomatic malaria among children under 5 years in Ghana","volume":"15","author":"Okyere","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb0480","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-3156.2012.02975.x","article-title":"Antigen persistence of rapid diagnostic tests in pregnant women in Nanoro, Burkina Faso, and the implications for the diagnosis of malaria in pregnancy","volume":"17","author":"Kattenberg","year":"2012","journal-title":"Trop Med Int Health TM IH"},{"key":"10.1016\/j.vaccine.2025.127971_bb0485","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12936-019-2987-4","article-title":"Systematic review of the status of pfhrp2 and pfhrp3 gene deletion, approaches and methods used for its estimation and reporting in plasmodium falciparum populations in Africa: review of published studies 2010-2019","volume":"18","author":"Agaba","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0490","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.3390\/tropicalmed5020102","article-title":"Evaluation of malaria diagnostic methods as a key for successful control and elimination programs","volume":"5","author":"Mbanefo","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0495","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0500","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ni.f.205","article-title":"Immunity to malaria: more questions than answers","volume":"9","author":"Langhorne","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0505","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1475-2875-8-312","article-title":"Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data","volume":"8","author":"Moorthy","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0510","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14760584.2021.1882309","article-title":"Correlates of malaria vaccine efficacy","volume":"20","author":"Stanisic","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127971_bb0515","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/21645515.2017.1381809","article-title":"Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine","volume":"14","author":"Moris","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127971_bb0520","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/14760584.2021.1981864","article-title":"Multi-functional antibody profiling for malaria vaccine development and evaluation","volume":"20","author":"Opi","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127971_bb0525","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41577-019-0158-z","article-title":"T cell-mediated immunity to malaria","volume":"19","author":"Kurup","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fdata.2021.672460","article-title":"Comprehensive data integration approach to assess immune responses and correlates of RTS,S\/AS01-mediated protection from malaria infection in controlled human malaria infection trials","volume":"4","author":"Young","year":"2021","journal-title":"Front Big Data"},{"key":"10.1016\/j.vaccine.2025.127971_bb0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/CMR.00025-08","article-title":"Acquired immunity to malaria","volume":"22","author":"Doolan","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2025.127971_bb0540","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4269\/ajtmh.18-0805","article-title":"Antibody correlates of protection from clinical plasmodium falciparum malaria in an area of low and unstable malaria transmission","volume":"103","author":"Hamre","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0545","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41577-019-0209-5","article-title":"Antibodies against plasmodium falciparum malaria at the molecular level","volume":"19","author":"Julien","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0550","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/INF.0b013e31822d1451","article-title":"Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria","volume":"30","author":"McCarra","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0555","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0560","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1016\/j.vaccine.2007.01.085","article-title":"WHO study group on measures of Malaria Vaccine efficacy. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation","volume":"25","author":"Moorthy","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0565","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-3024.2009.01144.x","article-title":"Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines","volume":"31","author":"O\u2019Meara","year":"2009","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0570","doi-asserted-by":"crossref","unstructured":"Moorthy VS, Reed Z, Smith PG, WHO Malaria Vaccine Advisory Committee. MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. Vaccine 2009;27:624\u20138. doi:https:\/\/doi.org\/10.1016\/j.vaccine.2008.11.034.","DOI":"10.1016\/j.vaccine.2008.11.034"},{"key":"10.1016\/j.vaccine.2025.127971_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.634508","article-title":"Progress and insights toward an effective placental malaria vaccine","volume":"12","author":"Gamain","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0580","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14760584.2021.1878028","article-title":"Transmission-blocking vaccines: harnessing herd immunity for malaria elimination","volume":"20","author":"Duffy","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127971_bb0585","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2875-9-82","article-title":"Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials","volume":"9","author":"White","year":"2010","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0590","series-title":"Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites","author":"Roestenberg","year":"2013"},{"key":"10.1016\/j.vaccine.2025.127971_bb0595","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1016\/j.vaccine.2012.04.088","article-title":"A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines","volume":"30","author":"Laurens","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0600","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00479-17","article-title":"Controlled human malaria infection: applications, advances, and challenges","volume":"86","author":"Stanisic","year":"2018","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127971_bb0605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","article-title":"Direct venous inoculation of plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres","volume":"14","author":"Mordm\u00fcller","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0610","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/infdis\/jiz410","article-title":"Dose-dependent infectivity of aseptic, purified, cryopreserved plasmodium falciparum 7G8 sporozoites in malaria-naive adults","volume":"220","author":"Laurens","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0615","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-0942","article-title":"Multi-dose priming regimens of PfSPZ vaccine: safety and efficacy against controlled human malaria infection in Equatoguinean adults","author":"Jongo","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0620","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/cid\/ciz740","article-title":"Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a plasmodium falciparum controlled human infection","volume":"70","author":"Achan","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2025.127971_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106225","article-title":"Innovative trial designs and analyses for vaccine clinical development","volume":"100","author":"Liu","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.vaccine.2025.127971_bb0630","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10124","article-title":"A 2020 vision for vaccines against HIV, tuberculosis and malaria","volume":"473","author":"Rappuoli","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.127971_bb0635","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.vaccine.2021.03.093","article-title":"Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019","volume":"39","author":"Vekemans","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0640","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001363","article-title":"Vaccinology in sub-Saharan Africa","volume":"4","author":"Mo\u00efsi","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb0645","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fpubh.2019.00056","article-title":"Vaccine production in Africa: a feasible business model for capacity building and sustainable new vaccine introduction","volume":"7","author":"Makenga","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb0650","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1016\/j.vaccine.2015.06.107","article-title":"Implementation workshop of WHO guidelines on evaluation of malaria vaccines: current regulatory concepts and issues related to vaccine quality, Pretoria, South Africa 07 Nov 2014","volume":"33","author":"Ho","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0655","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1016\/S2214-109X(24)00092-5","article-title":"Facilitating the development of urgently required combination vaccines","volume":"12","author":"Hausdorff","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb0660","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3389\/fimmu.2019.02412","article-title":"A viral-vectored multi-stage malaria vaccine regimen with protective and transmission-blocking efficacies","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0665","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3389\/fimmu.2018.02780","article-title":"Combination of RTS,S and Pfs25-IMX313 induces a functional antibody response against malaria infection and transmission in mice","volume":"9","author":"Brod","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131456","article-title":"Analysis of a multi-component multi-stage malaria vaccine candidate--tackling the cocktail challenge","volume":"10","author":"Boes","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb0675","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-018-0084-2","article-title":"Safety and efficacy of novel malaria vaccine regimens of RTS,S\/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP","volume":"3","author":"Rampling","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127971_bb0680","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.vaccine.2005.01.142","article-title":"Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research","volume":"23","author":"Heppner","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0685","author":"BioNTech"},{"key":"10.1016\/j.vaccine.2025.127971_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-35761-6.00004-3","article-title":"The vaccine industry","volume":"41-50","author":"Douglas","year":"2018","journal-title":"Plotkins Vaccines"},{"key":"10.1016\/j.vaccine.2025.127971_bb0695","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1473-3099(22)00139-6","article-title":"COVID-19 vaccine results might inform malaria vaccine strategies","volume":"22","author":"Abeywickrema","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0700","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0705","series-title":"A phase 1\/2b double blind randomised controlled trial of the efficacy, safety and immunogenicity of heterologous prime-boost immunisation with the candidate malaria vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 month old Burkinabe infants and children","author":"University of Oxford","year":"2016"},{"key":"10.1016\/j.vaccine.2025.127971_bb0710","series-title":"A Phase I challenge study to evaluate safety, immunogenicity, and efficacy of a malaria vaccine (rCSP adjuvanted with AP 10\u2013602 [GLA-LSQ]), in healthy adults","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0715","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiae062","article-title":"Recombinant full-length Plasmodium falciparum circumsporozoite protein\u2013based vaccine adjuvanted with Glucopyranosyl Lipid A\u2013Liposome Quillaja saponaria 21: results of Phase 1 testing with malaria challenge","volume":"229","author":"Friedman-Klabanoff","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0720","series-title":"A phase I\/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage plasmodium falciparum malaria vaccine candidate RH5.1\/AS01","author":"University of Oxford","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0725","series-title":"Phase 1 clinical trial with controlled human malaria infection (CHMI) for safety, protective efficacy, and immunogenicity of plasmodium falciparum malaria protein (FMP013) administered intramuscularly with ALFQ healthy malaria-na\u00efve adults","author":"U.S. Army Medical Research and Development Command","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0730","series-title":"Phase 1 clinical trial with controlled human malaria infection (CHMI) for safety, protective efficacy, and immunogenicity of plasmodium falciparum malaria protein (FMP014) administered intramuscularly with ALFQ healthy malaria-na\u00efve adults","author":"U.S. Army Medical Research and Development Command","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127971_bb0735","series-title":"Phase 1 randomized, dose-finding study to evaluate the safety, tolerability and immunogenicity of a novel malaria vaccine, MSP3-CRM-Vac4All\/ Alhydrogel\u00ae, in healthy adults","author":"Vac4All","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0740","first-page":"14","article-title":"Safety and immunogenicity of BK-SE36\/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial","author":"Ou\u00e9draogo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0750","series-title":"Safety and immunogenicity of the placental malaria vaccine candidate PAMVAC adjuvanted with Alhydrogel, GLA-SE or GLA-LSQ in healthy malaria-na\u00efve adults and healthy, lifelong malaria-exposed, nulligravid adult women","author":"University Hospital Tuebingen","year":"2018"},{"key":"10.1016\/j.vaccine.2025.127971_bb0755","series-title":"Double blind dose-escalating randomized controlled phase 1 study in malaria exposed adults of the safety and immunogenicity of Pfs25-EPA\/ Alhydrogel, a transmission blocking vaccine against plasmodium falciparum in Bancoumana, Mali","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2018"},{"key":"10.1016\/j.vaccine.2025.127971_bb0760","series-title":"Phase 1 study of the safety and immunogenicity of Pfs230D1M-EPA\/Alhydrogel and Pfs25M-EPA\/Alhydrogel, a transmission blocking vaccine against plasmodium falciparum malaria in adults in the US and Mali","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0765","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0770","series-title":"A phase Ia study to assess safety and immunogenicity of the plasmodium falciparum malaria vaccine candidate Pfs25-IMX313 in matrix-M1 adjuvant in healthy adults living in the UK","author":"University of Oxford","year":"2020"},{"key":"10.1016\/j.vaccine.2025.127971_bb0775","series-title":"A phase Ib age de-escalation and dose escalation open label clinical trial of the safety, immunogenicity and ex vivo efficacy of a candidate malaria vaccine Pfs25-IMX313\/matrix-M administered intramuscularly in healthy adults and young children in Tanzania","author":"University of Oxford","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0780","series-title":"A phase Ia clinical trial to assess the safety, immunogenicity and ex-vivo efficacy of new plasmodium falciparum malaria vaccine candidates ChAd63 Pfs-IMX313 alone and with MVA Pfs25-IMX313","author":"University of Oxford","year":"2017"},{"key":"10.1016\/j.vaccine.2025.127971_bb0785","series-title":"Safety, tolerability and plasmodium falciparum transmission-reducing activity of R0.6C vaccine adjuvanted with Alhydrogel alone or combined with matrix-M in healthy malaria-na\u00efve adults in the Netherlands","author":"McCall","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0790","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0795","series-title":"Clinical trial of PfSPZ vaccine administered by direct venous inoculation: dose optimization with heterologous challenge in healthy malaria-na\u00efve adults","author":"Sanaria Inc","year":"2018"},{"key":"10.1016\/j.vaccine.2025.127971_bb0800","author":"Sanaria Inc","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0805","series-title":"Phase 2 trial of safety, immunogenicity, and efficacy against plasmodium falciparum malaria of PfSPZ vaccine in children in Mali","author":"Sanaria Inc","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0810","series-title":"A clinical trial of a 3-dose, 28-day regimen of PfSPZ vaccine in healthy, malaria-na\u00efve, adult subjects to determine safety, tolerability and efficacy against heterologous CHMI conducted 14, 42 or 70 days after immunization","author":"Sanaria Inc","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0815","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2017"},{"key":"10.1016\/j.vaccine.2025.127971_bb0820","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0825","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0830","author":"Sanaria Inc","year":"2018"},{"key":"10.1016\/j.vaccine.2025.127971_bb0835","series-title":"Safety and protective efficacy of intravenous immunization with cryopreserved plasmodium falciparum sporozoites under Atovaquone\/Proguanil chemoprophylaxis","author":"University Hospital Tuebingen","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0840","series-title":"Safety and protective efficacy of genetically attenuated pf\u2206b9\u2206Slarp (PfSPZ-GA1) malaria parasites in healthy Dutch volunteers","author":"Sanaria Inc","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0845","series-title":"Safety and protective efficacy of genetically attenuated pf\u2206mei2 (also referred to as GA2) malaria parasites in healthy Dutch volunteers","author":"Roestenberg","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0850","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2019"},{"key":"10.1016\/j.vaccine.2025.127971_bb0855","series-title":"A phase I\/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage plasmodium vivax malaria vaccine candidate PvDBPII in matrix M1 in healthy adults living in the UK","author":"University of Oxford","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0860","series-title":"A phase IIa challenge study to assess efficacy of the plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK","author":"University of Oxford","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0865","series-title":"A phase Ia study to assess safety and immunogenicity of the plasmodium vivax malaria vaccine candidate Pvs25-IMX313 in matrix-M1 adjuvant in healthy adults living in the UK","author":"University of Oxford","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0870","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0875","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vaccine.2016.11.042","article-title":"Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S\/AS01 in endemic Africa","volume":"35","author":"Galactionova","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-295","article-title":"Modeling the public health impact of malaria vaccines for developers and policymakers","volume":"13","author":"Nunes","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0885","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0890","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001157","article-title":"Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine","volume":"9","author":"Smith","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0895","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032587","article-title":"Simulated impact of RTS,S\/AS01 vaccination programs in the context of changing malaria transmission","volume":"7","author":"Brooks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb0900","series-title":"Mathematical models of within-host and transmission dynamics to determine effects of malaria interventions in a variety of transmission settings","author":"Eckhoff","year":"2013"},{"key":"10.1016\/j.vaccine.2025.127971_bb0905","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4269\/ajtmh.2006.75.111","article-title":"Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa","volume":"75","author":"Maire","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb0910","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1475-2875-8-127","article-title":"Simulation of the cost-effectiveness of malaria vaccines","volume":"8","author":"Tediosi","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0915","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052224","article-title":"Health-seeking behaviour and cost of fever treatment to households in a malaria-endemic setting of northern Ghana: a cross-sectional study","volume":"11","author":"Dalaba","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127971_bb0920","first-page":"4","article-title":"Social implications of malaria and their relationships with poverty. Mediterr J Hematol","author":"Ricci","year":"2012","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2025.127971_bb0925","series-title":"Poverty and health\u00a0: WHO proposes a strategy for the African region","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.vaccine.2025.127971_bb0930","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb0935","author":"THE 17 GOALS | Sustainable Development"},{"key":"10.1016\/j.vaccine.2025.127971_bb0940","series-title":"Intolerable Burd. Malar. New Look Numbers Suppl. Vol. 641 Am. J. Trop. Med. Hyg.","first-page":"85","article-title":"The Economic Burden of Malaria","author":"Gallup","year":"2001"},{"key":"10.1016\/j.vaccine.2025.127971_bb0945","author":"Roll Back Malaria Partnership"},{"key":"10.1016\/j.vaccine.2025.127971_bb0950","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(11)60888-X","article-title":"Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study","volume":"378","author":"Scott","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127971_bb0955","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1093\/cid\/civ674","article-title":"Emergence of community-acquired, multidrug-resistant invasive nontyphoidal Salmonella disease in rural western Kenya, 2009\u20132013","volume":"61","author":"Oneko","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb0960","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12936-021-03973-y","article-title":"Insights from modelling malaria vaccines for policy decisions: the focus on RTS,S","volume":"20","author":"Galactionova","year":"2021","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000324","article-title":"Reducing plasmodium falciparum Malaria transmission in Africa: a model-based evaluation of intervention strategies","volume":"7","author":"Griffin","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0970","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1475-2875-12-126","article-title":"A mathematical model of the impact of present and future malaria vaccines","volume":"12","author":"Wenger","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0975","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004383","article-title":"Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends","volume":"4","author":"Ghani","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb0980","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0169-5347(02)02450-3","article-title":"Imperfect vaccines and imperfect models","volume":"17","author":"Smith","year":"2002","journal-title":"Trends Ecol Evol"},{"key":"10.1016\/j.vaccine.2025.127971_bb0985","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12916-015-0408-2","article-title":"The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models","volume":"13","author":"Penny","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb0990","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12936-015-0805-1","article-title":"Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study","volume":"14","author":"Pemberton-Ross","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb0995","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS, S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","volume":"387","author":"Penny","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127971_bb1000","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1186\/s12879-019-4467-4","article-title":"Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study","volume":"19","author":"Camponovo","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb1005","doi-asserted-by":"crossref","first-page":"e1782","DOI":"10.1016\/S2214-109X(22)00416-8","article-title":"Seasonal use case for the RTS,S\/AS01 malaria vaccine: a mathematical modelling study","volume":"10","author":"Thompson","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb1010","series-title":"Seasonal Malaria Vaccination (RTS,S\/AS01) and Seasonal Malaria Chemoprevention (SP\/AQ) Extension Study (RTSS-SMC)","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127971_bb1015","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb1020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pt.2010.12.011","article-title":"Uses of mosquito-stage transmission-blocking vaccines against plasmodium falciparum","volume":"27","author":"Smith","year":"2011","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2025.127971_bb1025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0001-706X(93)90013-2","article-title":"Minimal efficacy requirements for malarial vaccines to significantly lower transmission in epidemic or seasonal malaria","volume":"52","author":"Saul","year":"1993","journal-title":"Acta Trop"},{"key":"10.1016\/j.vaccine.2025.127971_bb1030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000211","article-title":"Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention","volume":"2","author":"Burgert","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb1035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40249-022-00981-1","article-title":"Leveraging mathematical models of disease dynamics and machine learning to improve development of novel malaria interventions","volume":"11","author":"Golumbeanu","year":"2022","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.vaccine.2025.127971_bb1040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/jiad101","article-title":"Modeling the impact of a highly potent plasmodium falciparum transmission-blocking monoclonal antibody in areas of seasonal malaria transmission","volume":"228","author":"Challenger","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb1045","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1016\/j.vaccine.2015.10.079","article-title":"Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data","volume":"33","author":"Galactionova","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb1050","article-title":"The costs of implementing vaccination with the RTS,S malaria vaccine in five sub-Saharan African countries","volume":"4","author":"Sicuri","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.vaccine.2025.127971_bb1055","article-title":"Costs of continuing RTS,S\/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries","volume":"16","author":"Baral","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-023-00274-0","article-title":"Modelling to inform next-generation medical interventions for malaria prevention and treatment","volume":"3","author":"Nekkab","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb1065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-011316","article-title":"Cost of introducing and delivering malaria vaccine (RTS,S\/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso","volume":"8","author":"Diawara","year":"2023","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb1070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12916-018-1095-6","article-title":"Modelling population-level impact to inform target product profiles for childhood malaria vaccines","volume":"16","author":"Hogan","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb1075","author":"OpenMalaria Wiki"},{"key":"10.1016\/j.vaccine.2025.127971_bb1080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12936-015-0969-8","article-title":"The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease","volume":"14","author":"Penny","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb1085","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4269\/ajtmh.2006.75.104","article-title":"Modeling a field trial of the RTS,S\/AS02A malaria vaccine","volume":"75","author":"Maire","year":"2006","journal-title":"Am J Tropical Med Hygiene"},{"key":"10.1016\/j.vaccine.2025.127971_bb1090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1475-2875-8-212","article-title":"The role of simple mathematical models in malaria elimination strategy design","volume":"8","author":"White","year":"2009","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb1095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4269\/ajtmh.2006.75.90","article-title":"An approach to model the costs and effects of case management of plasmodium falciparum malaria in sub-Saharan Africa","volume":"75","author":"Tediosi","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb1100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-015-1046-z","article-title":"Potential public health impact of RTS, S malaria candidate vaccine in sub-Saharan Africa: a modelling study","volume":"14","author":"Sauboin","year":"2015","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2025.127971_bb1105","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1016\/j.vaccine.2015.09.099","article-title":"Vaccine approaches to malaria control and elimination: insights from mathematical models","volume":"33","author":"White","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb1110","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/ncomms2840","article-title":"Transmission-blocking interventions eliminate malaria from laboratory populations","volume":"4","author":"Blagborough","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127971_bb1115","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1017\/S0031182008000280","article-title":"Efficacy model for mosquito stage transmission blocking vaccines for malaria","volume":"135","author":"Saul","year":"2008","journal-title":"Parasitology"},{"key":"10.1016\/j.vaccine.2025.127971_bb1120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4269\/ajtmh.2006.75.119","article-title":"The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania","volume":"75","author":"Hutton","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb1125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4269\/ajtmh.2006.75.131","article-title":"Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania","volume":"75","author":"Tediosi","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2025.127971_bb1130","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jval.2011.06.004","article-title":"Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan africa: analysis of uncertainties using a stochastic individual-based simulation model of plasmodium falciparum malaria","volume":"14","author":"Maire","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb1135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2016-000090","article-title":"Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa","volume":"2","author":"Winskill","year":"2017","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127971_bb1140","article-title":"Economic impact of introducing the RTS,S malaria vaccine: cost-effectiveness and budget impact analysis in 41 countries","volume":"4","author":"Sauboin","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.vaccine.2025.127971_bb1145","article-title":"Reducing malaria mortality at the lowest budget: an optimization tool for selecting malaria preventative interventions applied to Ghana","volume":"4","author":"Sauboin","year":"2019","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.vaccine.2025.127971_bb1150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233902","article-title":"Cost-effective analysis of childhood malaria vaccination in endemic hotspots of Bangladesh","volume":"15","author":"Sarker","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127971_bb1155","doi-asserted-by":"crossref","first-page":"260","DOI":"10.12688\/wellcomeopenres.16224.2","article-title":"Cost-effectiveness and public health impact of RTS,S\/AS01E malaria vaccine in Malawi, using a Markov static model","volume":"5","author":"Ndeketa","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2025.127971_bb1160","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb1165","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb1170","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb1175","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2025.127971_bb1180","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb1185","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1016\/j.vaccine.2014.04.019","article-title":"Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy","volume":"32","author":"Gessner","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127971_bb1190","author":"GSK"},{"key":"10.1016\/j.vaccine.2025.127971_bb1195","author":"Gavi, the Vaccine Alliance"},{"key":"10.1016\/j.vaccine.2025.127971_bb1200","author":"UNICEF"},{"key":"10.1016\/j.vaccine.2025.127971_bb1205","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127971_bb1210","article-title":"Safety, tolerability, and plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-Centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults","volume":"S1473-3099","author":"van der Boor","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127971_bb1215","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ymthe.2022.04.001","article-title":"Monoclonal antibodies for malaria prevention","volume":"30","author":"Aleshnick","year":"2022","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2025.127971_bb1220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria","volume":"387","author":"Wu","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb1225","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","article-title":"Safety and efficacy of a monoclonal antibody against malaria in Mali","volume":"387","author":"Kayentao","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127971_bb1230","series-title":"Safety and efficacy of L9LS, a human monoclonal antibody against plasmodium falciparum, in an age de-dscalation, dose-dscalation trial and a randomized, placebo-controlled, double-blind trial of children in western Kenya","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127971_bb1235","series-title":"Safety and efficacy of L9LS, a human monoclonal antibody against plasmodium falciparum, in a dose-escalation trial in adults and children and a randomized, double-blind trial of children in Mali","author":"National Institute of Allergy and Infectious Diseases (NIAID)","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127971_bb1240","series-title":"Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children","author":"Natama","year":"2024"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25012691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T22:21:34Z","timestamp":1766096494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25012691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":245,"alternative-id":["S0264410X25012691"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127971","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value profile for Malaria vaccines and monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127971"}}